Skip to main content
. 2021 Jan 8;17(2):e266–e277. doi: 10.1200/OP.20.00443

Fig 3.

Fig 3.

Probability of SIRT being cost effective at different cost-effectiveness thresholds. The probability of sorafenib being cost effective equals 100% minus the depicted probability of SIRT being cost effective. QALY, quality-adjusted life year; SIRT, selective internal radiotherapy.